Adherence
A Guide to Better Serving Burnt-out Physicians
Since March 2020, demands on the time and energy of physicians have never been ...
Three Key Insights About the Prescription Journey in 2022 and Beyond
As the U.S. enters a new phase and shifts from the crisis mode of ...
Reaching Prescribers Where Their Eyes Are—In the EHR
Among the tectonic shifts created by the pandemic is an increase in patient touchpoints, ...
Providing More Meaningful Support to Patients and Physicians Through Digital Engagement Tools
The acceleration in adopting digital technology in healthcare provides new opportunities for drug manufacturers ...
Using Data to Drive Patient Adherence, Population Health, and Brand Revenues
When pharma brands send patients or prescribers a message about reducing medication costs, how ...
Harnessing the Power of Mobile Patient Support for Patient Adherence
As the healthcare system continues to shift toward finding ways to support and inform ...
An Evolving Healthcare Ecosystem: Pharma’s Role in Solving SDoH and Health Equity Issues
The 16th Century English phrase, “A Jack of all trades is a master of ...
Driving Adherence with Point-of-Care Marketing
It’s no secret that drug adherence is a major problem, not only for patients, ...
Examining the Impact of COVID on Adherence and the Path Forward
One of the major concerns during the early days of the pandemic was how ...
Two Key Questions About Adherence/Compliance in 2021
PM360 asked experts in helping patients adhere to their treatment regimens how COVID will ...
8 of the Latest Solutions and Strategies to Improve Adherence
Each year, medication nonadherence costs the U.S. healthcare system hundreds of billions of dollars. ...
In-Workflow Tools Are Changing the Provider-Patient Conversation and Driving Adherence
For patients struggling with a serious medical condition, finally finding an effective treatment and ...
Why People with Diabetes are Hit Harder by COVID-19—And How to Help Them
As we continue to learn more about COVID-19 and its long-term effects, it’s clear ...
